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http://dx.doi.org/10.1016/j.jmii.2013Background: Mycoplasma pneumoniae is a common pathogen of respiratory tract infection in
children, and its correct and rapid diagnosis is a clinical challenge. Real-time polymerase chain
reaction (RT-PCR) has been used frequently for the detection of this pathogen.
Materials and methods: Medical records from all children with a clinical diagnosis of myco-
plasma pneumonia and whose respiratory samples were tested for M. pneumoniae (using RT-
PCR) during 2011 were reviewed retrospectively. We compared the sensitivity and specificity
of serological assays versus those of RT-PCR for diagnosis of M. pneumoniae infections. We also
reviewed retrospectively clinical characteristics, and laboratory and imaging findings of chil-
dren with laboratory evidence of M. pneumoniae infection.
Results: In 2011, 290 children were diagnosed to have mycoplasma pneumonia clinically and
had their respiratory samples tested for M. pneumoniae by RT-PCR. Fifty-four children (19%)
had a positive result. Meanwhile, 63% (182/290) of these children also underwent serological
tests, out of whom 44 (24%) were found to be positive for immunoglobulin M (IgM). Using
PCR as a gold standard, M. pneumoniae IgM assay was found to show a sensitivity of 62.2%
and a specificity of 85.5%. Positive and negative predictive values of IgM were 52.3% and
89.9%, respectively. In M. pneumoniae IgM-positive children, a negative PCR result was associ-
ated with more coinfection by other pathogens and longer duration of prehospitalization fever.
Bacterial loads of M. pneumoniae were not correlated with clinical outcomes.t of Pediatrics, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
(C.-Y. Lu), lmhuang@ntu.edu.tw (L.-M. Huang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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138 H.-Y. Chang et al.Conclusion: The majority of clinically diagnosed mycoplasma pneumonia was unconfirmed.
Mycoplasma pneumoniae IgM has poor sensitivity and a positive predictive value. Interpreta-
tion of Mycoplasma pneumoniae IgM should be done with caution.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Mycoplasma pneumoniae is a common cause of respiratory
tract infection in all age groups, including children and
adolescents. It has been reported to be the cause of up to
10e40% of all community-acquired pneumonia.1e3 Aware-
ness of Mycoplasma is nowadays widespread among pedia-
tricians and even among parents. However, confirmation of
M. pneumoniae infection is clinically challenging. Indis-
criminate use of macrolides has led to an increased resis-
tance to it in M. pneumoniae. Culture of this pathogen is
difficult to perform and time consuming. Detection of
antibody conversion or four-fold rise in antibody titers in
two consecutive sera samples collected 2 weeks apart in-
dicates an acute infection. However, this is also time
consuming and offers a diagnosis only retrospectively. In
addition, the enzyme-linked immunosorbent assay (ELISA)
methods that are currently being used widely for the
detection of Mycoplasma immunoglobulin G (IgG) are
mostly semiquantitative and not useful in detecting the
four-fold rise of antibody titers. The sensitivity and speci-
ficity of M. pneumoniae IgM remained elusive. It may
require 1e2 weeks for IgM antibodies to develop. All these
factors limited clinical use of serological assays in diag-
nosing M. pneumoniae infections. Although the real-time
polymerase chain reaction (RT-PCR) technology has ad-
vantages, it also has its limitations, such as being expen-
sive.4,5 Currently, diagnosis of M. pneumoniae infection
mainly relies on serological tests. However, PCR-based as-
says are increasingly being adopted, because recent studies
concluded that PCR is superior to serology for the diagnosis
of M. pneumoniae infection during its early phase.6,7
In this study, we compared the results of Mycoplasma
IgM and RT-PCR assays in a clinical setting. Because we did
not have other reference standards for diagnosing
M. pneumoniae infection, we evaluated the sensitivity and
specificity of Mycoplasma IgM for diagnosing M. pneumo-
niae infection using PCR as a gold standard. Clinical and
laboratory characteristics of patients with laboratory evi-
dence, either serology or PCR, were analyzed. Comparisons
were made between PCR-positive and PCR-negative pa-
tients among IgM-positive patients. In addition, the relation
between Mycoplasma loads and severity of disease was also
investigated.Materials and methods
This is a retrospective analysis of clinical information from
pediatric patients (aged 18 years), diagnosed to have
mycoplasma pneumonia, in a children hospital. An in-house
RT-PCR system for M. pneumoniae was established.Respiratory samples (throat swab, sputum, or pleural
effusion) of children with Mycoplasma infection-compatible
clinical symptoms (fever and cough with minimal or no
respiratory distress), physical findings (crackles or
wheezing on auscultation), and radiological findings (pat-
chy or linear infiltrates on chest X-ray) were checked for
M. pneumoniae DNA by RT-PCR on a clinical service basis.
Most of these children were also checked for M. pneumo-
niae IgG/IgM, blood culture, virus isolation, and urine
pneumococcal antigen when feasible.
Sensitivity, specificity, and positive and negative pre-
dictive values were calculated for IgM using PCR result as a
diagnostic standard.7 Clinical features, laboratory findings,
and chest radiographic findings for patients with positive
M. pneumoniae IgM or PCR were retrospectively reviewed.
The chest radiographic findings at admission were divided
into two patterns: bronchopneumonia or lobar pneumonia.
Bronchopneumonia was defined as increased nodular den-
sities along bronchial trees or/and an interstitial pattern on
unilateral or bilateral lung fields. Lobar pneumonia was
defined as a distinctive segmental or lobar consolidation.
Comparisons were made between PCR-positive and PCR-
negative patients.RT-PCR for M. pneumoniae
Samples for RT-PCR analysis were placed in tubes contain-
ing phosphate-buffered saline and were vortexed. DNA was
extracted from 200 mL of each sample using the Roche
MagNA Pure LC total nucleic acid isolation kit (MagNA Pure
LC 2.0; Roche, Basel, Switzerland) and finally eluted with
100 mL elution buffer. A quantitative RT-PCR method was
used to measure the load of M. pneumoniae. Primers MP-
Forward (CCAACCAAACAACAACgTTCA) and MP-Reverse
(TAACGGCAACACGTAATCAGGTC) along with the probe MP-
probe (6FAM-ACCTTGACTGGAGGCCGTTA-BHQ1) were used
to identify the Cytadhesin P1 (130 bp) target gene.8 RT-PCR
reaction was programmed by DyNAmo Flash Probe qPCR kit
(New England Biolabs, Vantaa, Finland) and LightCycler 1.5
instrument (Roche).M. pneumoniae serology
IgM or IgG antibodies were measured using the SeroMP IgM
or IgG kit (Savyon Diagnostics Ltd, Ashdod, Israel), which is
a semiquantitative ELISA, for the determination of anti-
bodies specific to M. pneumoniae. The antigen used in the
SeroMP kit is the P1 membrane protein, which is a major
immunogen of M. pneumoniae. Based on the manufac-
turer’s suggestion, a negative IgM or IgG reaction was
defined as <10 BU/mL, an equivocal IgM or IgG reaction as
RT-PCR versus serology for M. pneumoniae infection 13910e20 BU/mL, and a positive IgM or IgG reaction as
20 BU/mL.
Statistical analysis
We compared the data of two separate groups using the
Chi-square test or Fisher’s exact test for categorical vari-
ables and the ManneWhitney U test for continuous vari-
ables. A p value of <0.05 was considered significant. All the
statistical operations were two tailed and performed with
SPSS version 19 (SPSS Inc., Chicago, IL, USA).
Results
In 2011, in 290 pediatric patients with a clinical diagnosis of
mycoplasma pneumonia, RT-PCR assay for M. pneumoniae
was performed on the throat swab (n Z 278), sputum
(n Z 9), or pleural effusion (n Z 3). Fifty-four (19%) pa-
tients had positive results (50 throat swabs, 2 sputum, and 2
pleural effusion). In all PCR-positive and hospitalized pa-
tients (nZ 41), the PCR was performed 7.8  3.3 days after
disease onset. In total, 244 patients were hospitalized. M.
pneumoniae serology assays were carried out for 182
(74.6%) of these patients. Among them, 44 (24.2%) had a
positive IgM. In hospitalized patients who received both
PCR and serology assays, 31.9% (58/182) were positive for
either IgM or PCR. Twenty-three patients were positive for
both M. pneumoniae IgM and PCR at the same time (Fig. 1).
M. pneumoniae bacterial loads were also determined by RT-
PCR. Among all the PCR-positive patients, the median load
of M. pneumoniae was 5.4  105 copies/mL, ranging from
1.2  103/mL to 3.3  108/mL. Patients with a clinical
diagnosis of mycoplasma pneumonia or positive M. pneu-
moniae PCR (n Z 54) were encountered all year round.
PCR-positive case numbers in July and October seemedMP RT-PCR was performed in 290 pediatric patients 
with clinical diagnosis of mycoplasma pneumonia 
IgM (+) (23) 
MP IgM tested (182) 
PCR (+) (37) PCR (–) (145) 
Hospitalized (244) 
IgM (–) (14) IgM (+) (21)
 
IgM (–) (124) 
Figure 1. Flow chart of the study design and number of
cases analysis. Data in parentheses denote case numbers.
IgM Z immunoglobulin M; MP Z M. pneumoniae; RT-
PCR Z real-time polymerase chain reaction.higher than those in other months of the year (Fig. 2).
However, there was no clear seasonality variation.
Sensitivity, specificity, and positive and negative
predictive values of M. pneumoniae IgM and RT-PCR
Among all the hospitalized patients with a clinical diagnosis
of mycoplasma pneumonia, 182 received both M. pneu-
moniae PCR and IgM assays. The results are shown in
Table 1. Because there was no reference standard available
for the diagnosis of Mycoplasma infection, IgM assay for
M. pneumoniae was evaluated using M. pneumoniae PCR as
the “gold standard.” Sensitivity and specificity of IgM were
estimated to be 62.2% and 85.5%, respectively. Positive pre-
dictive value of IgM was 52.3% and negative predictive value
was 89.9%. A receiver operating characteristic (ROC) curve of
M. pneumoniae IgM was figured according to a different
cutoff value (Fig. 3). The ROC curve showed that 25 BU/mL
was the most adequate cutoff point of M. pneumoniae IgM.
Under such a cutoff value, sensitivity remained the same
(62.2%) and specificity increased a little to 90.3% (95% con-
fidence interval: 0.65e0.86; area under curve (AUC)Z 0.76).
By contrast, when IgM serology was used as a gold
standard, sensitivity and specificity of RT-PCR became
52.3% and 89.9%, respectively. Positive predictive value of
PCR was 62.2% and negative predictive value was 85.5%.
Clinical and laboratory findings in patients with
M. pneumoniae infections
Clinical features, laboratory, and chest radiographic find-
ings of hospitalized patients who had laboratory evidence
(either PCR or IgM) of M. pneumoniae infection (n Z 58)
were reviewed. Urine pneumococcus Ag was checked in 60%
(35/58) of these patients, with 9% (3/35) showing positive
results. About a quarter (15/58, 25.9%) of these patients
had coinfections with adenovirus, pneumococcus, or others
(Table 2). Patients with coinfections (n Z 15) were
excluded from further analysis. The mean age of the pa-
tients was 7.6  3.8 years, and male-to-female ratio was
0.72:1. All patients had fever and cough. The total duration
of fever was 8.3  4.2 days (5.7  3.5 days prior to
admission and 2.5  3.0 days after admission). About two-Figure 2. Number of patients with positive and negative
Mycoplasma pneumoniae RT-PCR results according to months
of the year. RT-PCR Z real-time polymerase chain reaction.
Table 1 Sensitivity, specificity, and positive and negative
predictive values of Mycoplasma pneumoniae IgM using
real-time PCR as a diagnostic standard
PCR (þ) PCR () Total
IgM (þ)a 23 21 44
IgM (e) 14 124 138
Total 37 145 182
Sensitivity 23/37 Z 62.2%
Specificity 124/145 Z 85.5%
PPV 23/44 Z 52.3%
NPV 124/138 Z 89.9%
a An IgM titer value of 20 BU/mL was defined as positive.
IgM Z immunoglobulin M; NPV Z negative predictive value;
PCR Z polymerase chain reaction; PPV Z positive predictive
value.
140 H.-Y. Chang et al.thirds (27/43, 63%) of them had fever for over 7 days. On
average, fever subsided 1.9 days after the first dose of
azithromycin.
The majority of patients had abnormal breathing sounds,
and nearly one-fourth of the patients had mild chest wall
retractions. Lobar pneumonia and bronchopneumonia
accounted for 98% of RT-PCR-positive patients. Chest X-ray
revealed lobar pneumonia in two-thirds (27/43, 63%) of the
patients. One-fourth (26%, 11/43) of them had pleural
effusion, as confirmed by chest echo. Three children
received thoracocentasis and two of them had positive M.
pneumoniae RT-PCR result from pleural effusions. Skin rash
was noted in three (7%) patients. Patients in whom antibody
determination was performed 7 days or more after the
onset of fever were more likely to be positive for IgM [17/21
(81%) vs. 6/16 (38%), respectively; p Z 0.03].
Among these 37 hospitalized, M. pneumoniae PCR-
positive patients, eight were treated with azithromycin
prior to hospitalization. After hospitalization, five of these
eight patients received a second course of azithromycin. By
contrast, 25 of 29 patients who were not treated withFigure 3. ROC curve of Mycoplasma pneumoniae IgM.
Sensitivity and specificity were 62.2% and 90.3%, respectively
(95% CI Z 0.65e0.86; area under curve (AUC) Z 0.76) at
25 BU/mL, the most adequate cutoff point of IgM. AUC = area
under the curve; CIZ confidence interval; IgMZ immunoglobulin
M; ROC Z receiver operating characteristic.macrolides prior to hospitalization received azithromycin
treatment after hospitalization. Overall, 11% (4/37) of the
patients did not receive any mycoplasma-specific treat-
ment throughout their clinical courses. Fever subsided in
2.5  4.7 days after the first postadmission dose of azi-
thromycin. Patients who received macrolide treatment
prior to hospitalization (n Z 8) had a longer total duration
of fever than those who did not (n Z 29) (14.4  7.5 vs.
7.8  2.8 days; p Z 0.001). Patients who were not treated
with macrolides (n Z 4) had an average fever duration of
8.3  3.6 days, which is not significantly different from
those treated with azithromycin (9.3  5.1 days, n Z 35;
p Z 0.73).
Only two patients needed ventilator support due to
impending respiratory failure. Both of them had lung
consolidation and pleural effusion. One of them was coin-
fected with adenovirus and complicated with acute respi-
ratory distress syndrome. However, no evidence of
coinfection could be found in the other patient who was
intubated. He was then extubated within 1 week. Almost all
patients had good outcome and recovered without any
complications. Only one patient had a sequela of neuro-
logical regression due to the complication of extracorporeal
membrane oxygenation (ECMO) settings for a period of
time.
Among patients with positive M. pneumoniae IgM, those
with negative PCR results had more coinfections than those
whose PCR results were positive (Table 2). When patients
with coinfections (nZ 32) were excluded, 20 (63%) patients
were also found to be positive for M. pneumoniae PCR and
the other 12 (37%) were PCR negative. Clinical and labo-
ratory findings of these two groups were compared
(Table 3). The duration of fever prior to hospitalization in
PCR-positive group was 6.7  3.2 days, which was signifi-
cantly longer than that of PCR-negative group (4.7  4.8
days; p Z 0.04). The total duration of fever was not
significantly different between the two groups.
Among the 43 hospitalized patients who were positive
for M. pneumoniae PCR or IgM and had no detectable
coinfections, 27 (63%) belonged to lobar pneumonia group,
whereas 16 (37%) were classified as bronchopneumonia
group. Comparisons of parameters such as disease severity,
including duration of fever, duration of hospitalization,
intensive care unit (ICU) stay, white blood cell (WBC)
counts, M. pneumoniae PCR load, ventilator requirement,
and clinical outcome between these two groups revealed
no significant differences (Table 4). Furthermore, we also
compared disease severity parameters, including fever
duration, hospitalization, ICU stay, WBC counts, C-reactive
protein, and treatment requirements for different
M. pneumoniae PCR loads (e.g., 1  104/mL, 1  105/mL,
1  106/mL, and 1  107/mL). There was no obvious as-
sociation between M. pneumoniae load and disease
severity.Discussion
Our results showed that in pediatric patients who were
diagnosed with mycoplasma pneumonia clinically, only a
small proportion of them were confirmed by laboratory
tests, either the detection of M. pneumoniae IgM by ELISA










Adenovirus 8 2 6
Pneumococcus 2 1 1
Adenovirus plus pneumococcus 1 1
Influenza B 2 2
Coxsackievirus B5 1 1
EpsteineBarr virus 1 1
Total 15 3 9 3
a Adenovirus, influenza B, and Coxsackievirus B5 were identified by virus culture of throat swabs. EpsteineBarr virus was diagnosed by
serology. Pneumococcus was diagnosed by urine pneumococcal antigen.
IgM Z immunoglobulin M; PCR Z polymerase chain reaction.











n Z 43 n Z 20 n Z 12 n Z 11
Age (y) 7.6  3.8 6.9  3.7 7.0  3.0 9.5  4.3 1
Sex (male) 18 (42%) 9 (45%) 3 (25%) 6 (55%) 0.26
Underlying disease 10 (23%) 4 (20%) 5 (54%) 1 (9%) 0.19
Contact history 15 9 2 2 0.24
Use of antibiotics prior
to hospitalization
20 7 4 9 0.42
Hospitalization (d) 5.7  4.1 5.1  2.8 7.7  6.2 4.7  2.8 0.3
ICU admission 5 (12%) 1 (5%) 3 (25%) 1 (9%) 0.14
Duration of fever (d)
Prior to admission 5.7  3.5 6.7  3.2 4.7  4.8 5.3  1.5 0.04
After admission 2.5  3.0 2.4  2.9 3.0  4.3 2.3  1.3 0.25
Total duration 8.3  4.2 9.1  4.3 7.7  5.4 7.6  1.9 0.17
Cases 7 d 27 (63%) 14 (70%) 5 (42%) 8 (73%) 0.24
Fever duration after first
dose of azithromycin
1.9  2.8 1.9  2.7 3.9  5.3 1.5  1.5 0.1









Platelets (103/mL) 248 (128e821) 266 (178e531) 279 (162e821) 192 (128e316) 0.74
Hemoglobin (g/dL) 12.7 (8.2e15.3) 12.7 (8.2e14.5) 12.6 (8.5e13.6) 12.6 (11.3e15.3) 0.37














30.5 (20.2e112.8) NA 0.33
a Cases with coinfections were excluded.
b Comparisons were made between PCR(þ)/IgM(þ) and PCR(e)/IgM(þ) groups. Chi-square test or Fisher’s exact test was performed for
categorical variables and the ManneWhitney U test for continuous variables.
Data are presented as n (%) or mean  SD.
CRPZ C-reactive protein; ICUZ intensive care unit; IgMZ immunoglobulin M; NAZ not applicable; PCRZ polymerase chain reaction;
SD Z standard deviation; WBC Z white blood cell.
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Table 4 Comparison of clinical parameters between patients with lobar pneumonia and those with bronchopneumonia in 43
patients with positive Mycoplasma pneumoniae RT-PCR or IgM
Lobar Bronchopneumonia p
n Z 27 n Z 16
Duration of fever (d) 8.2  3.8 8.5  4.8 0.88
Hospitalization (d) 5.3  2.7 6.4  5.8 0.75
ICU (3) (2) 0.34
Lab findings (median, minemax)
WBC (/mL) 6790 (4270e15,520) 8975 (2040e27,260) 0.13
CRP (mg/dL) 3.8 (0.4e17.2) 4.7 (0e24.4) 0.8
M. pneumoniae PCR load (copies/mL) 4.2  105 2.9  104 0.14
IgM value (BU/mL) 40.8 (24.7e114.4) 42.8 (20.3e121.1) 0.99
Treatment requirement
O2 2 0 0.52
Thoracocentesis 2 0 0.52
Mechanical ventilation 1 0 1
Outcome
Complication 0 0 NA
Sequela 0 0 NA
Data are presented as n (%) or mean  standard deviation. Patients with detectable coinfections were excluded. CRP Z C-reactive
protein; ICU Z intensive care unit; IgM Z immunoglobulin M; NA Z not applicable; RT-PCR Z real-time polymerase chain reaction;
WBC Z white blood cell.
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diagnosis of mycoplasma pneumonia was common. The
majority of the patients were treated with azithromycin.
Although a proportion of these Mycoplasma-negative pa-
tients might have been infected by azithromycin-sensitive
pathogens such as Chlamydia and could still be benefited
from macrolide usage, overuse of macrolides is obviously
an immediate concern. Reliable, rapid, and easy-to-
perform tests for the diagnosis of M. pneumoniae in-
fections are helpful in guiding azithromycin usage and
preventing further selection of macrolide-resistant M.
pneumoniae.
A great discrepancy was noted between M. pneumoniae
IgM and RT-PCR results. Only 12.6% (23/182) of patients who
underwent both tests showed positive results in both at the
same time. RT-PCR failed to detect M. pneumoniae DNA in
47.7% of patients who were positive for M. pneumoniae IgM.
When RT-PCR was used as a diagnostic standard, a positive
M. pneumoniae IgM indicated true acute M. pneumoniae
infection in about half of cases. This might be explained by
the fact that Mycoplasma IgM can remain detectable for
several months after infections. Therefore, detection of
Mycoplasma IgM does not necessarily confirm acute infec-
tion. When patients are tested negative for M. pneumoniae
IgM, in about 86% of cases they are not truly infected by M.
pneumoniae. The specificity of M. pneumoniae IgM can be
elevated further from 85.5% to 90.3% by increasing the
cutoff value from 20 BU/mL to 25 BU/mL, but it does not
change the sensitivity (62.2%).
Many studies have also compared PCR and serological
tests for the diagnosis of M. pneumoniae.5,9,10 Beersma
et al9 evaluated 12 commercial EIA assays by paired sera
and used PCR as a gold standard. The sensitivity ranged
widely from 35% to 77% and specificity from 49% to 100%.
Our results were in line with these earlier reports.It is well known that a positive conversion or a significant
increase in IgG antibody titer in paired sera taken at least 2
weeks apart indicates an acute infection. However, taking
two consecutive blood samples 2 weeks apart is too late for
guiding treatment decisions. Sometimes, repeated blood
sampling is simply impossible in children. Our current study
showed that two consecutive blood samples were collected
from no more than 10% of pediatric patients with clinical
diagnosis of mycoplasma pneumonia in our routine clinical
practice.
In addition, our study also confirmed earlier reports that
M. pneumoniae IgM assay performed in the first week after
disease onset frequently yielded negative results.6,11 Obvi-
ously, M. pneumoniae IgM titer might have not increased to a
detectable level in the first week after fever onset. This
phenomenon also hindered early detection, which is highly
desired in the clinical setting for guiding treatment. By
contrast, the sensitivity of RT-PCR decreases as the duration
between symptom onset and sample collection increases.12
PCR-based tests have become increasingly important for
the early diagnosis of M. pneumoniae infections. However,
RT-PCR for M. pneumoniae infection is not perfect either.
Colonization or prolonged shedding from previous infection
episodes may account for the M. pneumoniae identified by
RT-PCR. An earlier study showed that persistent carriage of
M. pneumoniae DNA in the throat is common following an
acute infection.7 In patients with M. pneumoniae infection,
M. pneumoniae PCR load decreased over time, with a me-
dian period of 45e52 days.7 A threshold of 104 genomic DNA
copies per milliliter was proposed to distinguish clinical
infection from carriage.13 However, the cutoff value is not
generally accepted. The true prevalence of asymptomatic
carriage of M. pneumoniae in healthy children is unknown.
Studies have detected low M. pneumoniae carrier rates of
0.1e13.5% in healthy individuals.14,15 We cannot exclude
RT-PCR versus serology for M. pneumoniae infection 143the possibility that some of the M. pneumoniae detected by
RT-PCR in our study were actually innocent bystanders, and
not real pathogens. Therefore, no single test that can be
reliable for the diagnosis of M. pneumoniae infection is
available. A combination of various tests is probably the
most reliable approach.12
It was reported that the incidence of M. pneumoniae
infection does not vary greatly with seasons, but the pro-
portion of patients with M. pneumoniae pneumonia is
greatest during the summer and early fall in regions with
temperate climate.16,17 Our study showed results in line
with this finding. The highest numbers of PCR-confirmed
cases were observed in July and October in our study.
Pneumonia caused by M. pneumoniae is described as
walking pneumonia because the patients normally appear
relatively well without respiratory distress. Chest radio-
graphic findings were frequently discordant with clinical
presentations and lab findings.18,19 Again, our study results
were compatible with previous reports; two-thirds (66%) of
our patients showed lung consolidation, but only very few
of them had mild tachypnea and leucocytosis. The majority
showed no obvious respiratory distress and recovered
without any complication. Prolonged fever was not un-
common in our cases. The total fever duration of PCR- or
IgM-positive, hospitalized cases in this study was as long as
8.3  4.2 days. An earlier report showed that the total
fever duration of mycoplasma pneumonia was about
5.5e6.5 days, and older patients tended to have a longer
fever duration.20 Another report showed that children with
M. pneumoniae infection frequently have a fever duration
of 6 days or more prior to admission.21 In patients with M.
pneumoniae infection, response to macrolide treatment is
usually good. In the current study, fever subsided 1.9  2.8
days after the first dose of azithromycin. The reason why
fever duration seemed longer in the current study is un-
clear. In the past few years, the prevalence of macrolide-
resistant M. pneumoniae has been increasing in Taiwan
and elsewhere. This might partly underlie the long fever
duration observed in the current study. However, macrolide
resistance is beyond the scope of this study.
Interestingly, evidence of lobar pneumonia on chest
radiograph and higher bacterial loads detected by RT-PCR
were not associated with severity among RT-PCR-positive
patients in our study. An earlier report showed that the
mean higher M. pneumoniae loads were associated with
more advanced respiratory disease.22 In their study, M.
pneumoniae loads were significantly higher in hospitalized
patients than in outpatients. Our analysis focused on hos-
pitalized patients alone and, hence, may have inadequate
power to show correlations between bacterial loads and
disease severity.
When comparisons were made between patients with
positive and negative M. pneumoniae PCR among IgM-
positive patients, the duration of fever prior to hospitali-
zation was longer and that after hospitalization was shorter
in the PCR-positive group, suggesting that hospitalization
was delayed in that group. Possible explanations for this are
that some of the PCR-positive, IgM-negative patients were
actually not infected by M. pneumoniae, and also that
symptoms of Mycoplasma infections are usually mild
despite fever. They were seldom hospitalized unless fever
persisted for a long time.Limitations do exist in our current study. First, in a
retrospective study like this, timing of blood and throat
swab sampling varied greatly from case to case. This might
have affected the values of IgM and bacterial loads signif-
icantly, making interpretation of these data difficult. Sec-
ond, having no gold standard for M. pneumoniae infection,
such as four-fold rise of IgG antibodies in paired serum, is
another major limitation of the current study. Using throat
swab RT-PCR assay as a gold standard for estimating
sensitivity of M. pneumoniae IgM is not irrefutable. PCR
assays may have false-negative results due to inhibitors in
samples, poor technique, or timing of sample collection.
Contamination can happen, leading to false-positive re-
sults.4,12,23,24 PCR alone is frequently insufficient for the
diagnosis of M. pneumoniae infection. Clinically, interpre-
tation of Mycoplasma IgM or PCR results should be consid-
ered with caution. A combination of PCR plus serology
assays as an early diagnostic testing for patients with
compatible clinical manifestations may yield the most
reliable results.
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